Home・Список акций・PTC Therapeutics Inc

PTC Therapeutics Inc

Закрыт

СекторЗдравоохранение

73.06 3.5

Купить Продать

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

72.06

Макс.

73.3

Ключевые показатели
By Trading Economics
Доход	86M 83M
Продажи	88M 361M
P/E Средняя по отрасли	7.597 68.51
Прибыль на акцию	0.92
Рентабельность продаж	23.16
Сотрудники	991
EBITDA	198M 162M

Рекомендации
By TipRanks
Рекомендации	Покупка
Прогноз на 12 месяцев	+34.55% upside

Дивиденды
By Acuity
Следующий отчет о доходах	3 нояб. 2026 г.

Рыночная статистика
By TradingEconomics
Рыночная капитализация	-603M 5.7B
Предыдущая цена открытия	69.56
Предыдущая цена закрытия	73.06

Новостные настроения

By Acuity

55%

45%

264 / 340 Рейтинг в Healthcare

PTC Therapeutics Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

7 авг. 2026 г., 21:02 UTC

PTC Therapeutics Inc shares are lower in after-market hours, reversing a trend of higher finishes over the past five sessions. No specific news was identified.

6 авг. 2026 г., 19:56 UTC

PTC Therapeutics Inc. is higher today, having reached a peak earlier in the session. No specific news was identified to explain the price action.

5 авг. 2026 г., 19:26 UTC

News

PTC Therapeutics Inc. will participate in upcoming investor conferences. Shares are lower today, remaining near the lower end of their one-month range.

4 авг. 2026 г., 20:07 UTC

PTC Therapeutics shares are higher today, buoyed by positive market sentiment amid a significant decline in crude oil prices.

3 авг. 2026 г., 19:46 UTC

News

PTC Therapeutics reported second-quarter revenue of $360.52 million and raised its full-year outlook to $1.18 billion to $1.28 billion, with shares advancing today.

31 июл. 2026 г., 21:01 UTC

PTC Therapeutics Inc shares rose in after-market trading, despite broader market concerns over inflation and interest rates amid rising crude oil prices.

30 июл. 2026 г., 22:31 UTC

News

PTC Therapeutics raised its 2026 revenue guidance after reporting strong Q2 results, with EPS of $0.92 exceeding estimates. Shares are higher in after-market trading.

29 июл. 2026 г., 18:26 UTC

PTC Therapeutics Inc shares are lower today, reflecting a broader decline. Market participants await the Federal Reserve's interest rate decision this afternoon.

28 июл. 2026 г., 18:31 UTC

News

PTC Therapeutics shares are lower as analysts anticipate a 5.6% revenue decline in Q2, contrasting with last year's growth of 24.2%.

27 июл. 2026 г., 20:06 UTC

PTC Therapeutics Inc shares are lower today amid broader market declines, influenced by falling oil prices and Treasury yields ahead of the Federal Reserve meeting.

22 июл. 2026 г., 17:16 UTC

PTC Therapeutics shares are lower today, trading near the lower end of their one-month range amid rising crude oil prices affecting the broader market.

21 июл. 2026 г., 18:01 UTC

PTC Therapeutics shares are higher today, reflecting positive market sentiment. The stock remains near the lower end of its one-month range.

20 июл. 2026 г., 19:56 UTC

News

PTC Therapeutics shares are lower as Wells Fargo cuts price target to $93.00 from $95.00 while keeping an Overweight rating.

Сравнение c конкурентами

Изменение цены

PTC Therapeutics Inc Прогноз

Целевая цена

By TipRanks

34.55% рост

Прогноз на 12 месяцев

Средняя 98.64 USD 34.55%

Максимум 130 USD

Минимум 70 USD

Основано на мнении 11 аналитиков Wall Street, спрогнозировавших целевые цены для PTC Therapeutics Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

11 ratings

Покупка

Удержание

Продажа

Основано на мнении 11 аналитиков, присваивавших рейтинги акциям PTC Therapeutics Inc – Данные за последние 3 месяца.

Настроения

By Acuity

264 / 340Рейтинг в Здравоохранение

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

О компании PTC Therapeutics Inc

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.